| |||||||||||||||||
|
IMS is proud of our research heritage and the benefits this research delivers to patients and the healthcare community. IMS’s information has been cited in hundreds of scholarly and peer-reviewed articles.
Below is a bibliography of selected publications and studies, from years 2004-2007, citing IMS information:
Allen-Ramey FC; Bukstein D; Luskin A; Sajjan SG; Markson LE. “Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy.” J Manag Care Pharm. 2006; 12(4):310-21
Arellano F, Wentworth CE, Arana A, Fernandez C, Paul C. "Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis." Journal of Investigative Dermatology, 9 November 2006
Arellano FM, Ulcickas Yood M, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. “Use of Cyclo-Oxygenase 2 Inhibitors (COX-2) and Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in UK and USA Populations. Implications for COX-2 cardiovascular profile.” Pharmacoepidemiology and Drug Safety 2006;15:861-872.
Bahls C, “Special Focus: Migraine,” American College of Physicians Observer, June 2005, 10-11.
Black L, Naslund MJ, Gilbert TD Jr, Davis EA, Ollendorf DA. "An Examination of Treatment Patterns and Costs of Care Among Patients with Benign Prostatic Hyperplasia." The American Journal of Managed Care 2006;12(4):S99-S110.
Blazer D G, Hybels C F, Fillenbaum, G G, Pieper C F, “Predictors of Antidepressant Use Among Older Adults: Have They Changed Over Time?” American Journal of Psychiatry, April 2005, 705-710.
Brassard P; Kezouh A; Suissa S. “Antirheumatic drugs and the risk of tuberculosis.” Clin Infect Dis. 2006; 43(6):717-22
Colman E, “Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants,” Annals of Internal Medicine, September 6, 2005, 380-385.
Condon T P, National Institute on Drug Abuse, “Drug Abuse in the 21st Century - What Problems Lie Ahead for the Baby Boomers?” National Institutes of Health, Department of Health and Human Services, September 16, 2004.
Cook A, “Testosterone therapy: The answer for aging men?” Mayo Clinic Health Information, July 12, 2004.
Danzon P M with Wang Y R and Wang L, “The Impact of Price Regulation on the Launch Delay of New Drugs,” Health Economics, September 2004, 269-292.
Eisenberg SS. “Building the case for asthma as a disease management program.” Disease Manag. 2004; 7(3):202-15
Fenter TC; Runken MC; Black L; Eaddy M. ”Finasteride versus dutasteride: a real-world economic evaluation.” Am J Manag Care. 2007; 13 Suppl 1:S23-8
Fischer M A, Schneeweiss S, Avorn J, and Solomon D H, “Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors,” NEJM, November 18, 2004, 2187-2194.
Fisher Wilson J, “Cheaper Drugs in Foreign Markets Increase The Focus on Domestic Drug Prices,” Annals of Internal Medicine, April 2004, 677-680.
Garnett WR; Gilbert TD; O'Connor P. “Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.” Clinical Ther. 2005; 27(7):1092-103
Gianfrancesco F; Rajagopalan K; Goldberg JF; Wang RH "Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications.” Bipolar Disord. 2007; 9(3):252-61
Gilbert TD, Smith D, Ollendorf DA. “Patterns of Use, Dosing, and Economic Impact of Biologic Agent Use in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study.” BMC Musculoskeletal Disorders 2004;5:36.
Goodman J C, “Drug Reimportation: The Free Trade Solution,” National Center for Policy Analysis, February 16, 2005.
Guda N M, Vakil N, “Proton pump inhibitors and the time trends for esophageal dilation,” Am J Gastroenterol, May 2004, 797-800.
Hawkins R G, Houston M C, “Population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis,” Am J Hypertens, June 18, 2005, 744-749.
Hoffman JM, Shah ND, Vermeulen LC, Hunkler RJ, Hontz KM “Projecting future drug expenditures - 2004,” American Journal of HealthSystem Pharmacy, January 15, 2004, 145-158.
Hoffman JM, Shah ND, Vermeulen LC, Hunkler RJ, Hontz KM “Projecting future drug expenditures - 2005,” American Journal of HealthSystem Pharmacy, January 15, 2005, 149-167.
Hoffman JM, Shah ND, Vermeulen LC, Schumock GT, Grim P, Hunkler RJ, Hontz KM “Projecting future drug expenditures - 2006,” American Journal of HealthSystem Pharmacy, January 15, 2006, 123-138.
Hoffman JM, Shah ND, Vermeulen LC, Schumock GT, Grim P, Hunkler RJ, Hontz KM “Projecting future drug expenditures - 2007,” American Journal of HealthSystem Pharmacy, February 1, 2007, 298-314.
Hopkins Tanne J, “US doctors and patients are split on approval of generic thyroid hormone,” British Medical Journal, July 24, 2004, 329.
Issa MM; Runken MC; Grogg AL; Shah MB Emory. “A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.” Am J Manag Care. 2007; 13 Suppl 1:S10-6
Jick SS; Jick H. “Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.” Contraception. 2006; 74(4):290-2
Jick SS; Jick H. “The contraceptive patch in relation to ischemic stroke and acute myocardial infarction.” Pharmacotherapy. 2007; 27(2):218-20
Jick SS; Kaye JA; Russmann S; Jick H. “Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.” Contraception. 2006; 73(3):223-8.
Joyce AT, Harrison DJ, Loebel AD, Carter CT, Ollendorf DA. “Effect of Initial Ziprasidone Dose on Length of Therapy in Schizophrenia.” Schizophrenia Research 2006;83(2-3):285-292.
Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA. “Impact of Atypical Antipsychotics on Outcomes of Care in Schizophrenia.” The American Journal of Managed Care 2005;11(8):S254-S261.
Joyce AT, Iacoviello JM, Nag S, Sajjan S, Jilinskaia E, Throop D, Pedan A, Ollendorf DA, Alexander CM. “End Stage Renal Disease-Associated Managed Care Costs Among Patients With and Without Diabetes.” Diabetes Care 2004;27:2829-2835.
Jumadilova Z, Varadharajan S, Girase P, Ollendorf DA. “Retrospective Evaluation of Outcomes in Patients with Overactive Bladder Receiving Tolterodine Versus Oxybutynin.” American Society of Health-System Pharmacists, 2006;63:2357-2364.
Keating KN; Friedman HS; Perfetto EM. “Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.” Curr Med Res Opin. 2006; 22(2):327-33
Kuntze, MD, Daniel A. Ollendorf, MPH "Reduced Mortality Rate after Intensive Statin Therapy in Managed-care Patients.”, Value In Health, 2007; 10:2,:161-169
Lee PP; Levin LA; Walt JG; Chiang TH; Doyle JJ; Stern LS; Dolgitser M "The impact of glaucoma coding in a large claims database.” American Journal of Ophthalmology. 2007; 143(5):867-70
Lee WC; Arcona S; Thomas SK; Wang Q; Hoffmann MS; Pashos CL. “Effect of comorbidities on medical care use and cost among refractory patients with partial seizure disorder.” Epilepsy Behav. 2005; 7(1):123-6
Lee WC; Hoffmann MS; Arcona S; D'Souza J; Wang Q; Pashos CL. “A cost comparison of alternative regimens for treatment-refractory partial seizure disorder: an econometric analysis.” Clin. Ther. 2005; 27(10):1629-38
Leslie L K,Newman T B, Chesney P J, Perrin J M, “The Food and Drug Administration's Deliberations on Antidepressant Use in Pediatric Patients,” Pediatrics, July 2005, 195.
MacDougall C, Powell J P, Johnson C K, Edmond M B, Polk R E, “Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals,” Clin Infect Dis, August 14, 2005, 435-40.
MacDougall DA; Feliu AL; Boccuzzi SJ; Lin J "Economic burden of deep-vein thrombosis, pulmonary embolism, and post thrombotic syndrome.: Am J Health Syst Pharm. 2006: 63 (20 Suppl 6):S5-15
McLaughlin T; Geissler EC; Wan GJ. ”Comorbidities and associated treatment charges in patients with anxiety disorders.” Pharmacotherapy. 2003;23(10):1251-6
McLaughlin TP; Khandker RK; Kruzikas DT; Tummala R. “Overlap of anxiety and depression in a managed care population: Prevalence and association with resource utilization.” J Clin Psychiatry, 2006; 67(8):1187-93
Naslund M; Black L; Eaddy M; Batiste LR "Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs." Am J Manag Care. 2007; 13 Suppl 1:S17-22
Oberholzer-Gee F and Noorein Inamdar S, “Merck's Recall of Rofecoxib — A Strategic Perspective,” NEJM, November 2005, 97-105.
Ollendorf D, Joyce A, Rucker M. “Rate of New-Onset Diabetes Among Patients Treated With Atypical or Conventional Antipsychotic Medications for Schizophrenia”. Medscape General Medicine, 2004;6:1-12.
Ollendorf DA, Lidsky L. “Infliximab Drug and Infusion Costs Among Patients with Crohn’s Disease in a Commercially-Insured Setting.” American Journal of Therapeutics 2006;13:502-506.
Ollendorf DA, Massarotti E, Birbara C., Burgess S. ”Frequency, Predictors, and Economic Impact of Upward Dose Adjustment of Infliximab in Managed Care Patients with Rheumatoid Arthritis.” Journal of Managed Care Pharmacy 2005;11(5):383-393.
Packer C, Stevens A, Cook A, Raftery J, “Diffusion of thromboysis for acute myocardial infraction from 1981 to 2000 In England: trend analysis and comparison with need,” International Journal of Tech Assess Health Care, September 2004, 531-536.
Perfetto EM; Subedi P; Jumadilova Z. “Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.” Am J Manag Care. 2005; 11(4 Suppl):S150-7
Prescott JD; Factor S; Pill M; Levi GW. “Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.” J Manag Care Pharm. 2007; 13(1):44-52
Rajagopalan R; Iyer S; Perez A. “Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.” Diabetes Obes Metab. 2005; 7(2):161-9
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT. “Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clinical Ther. 2004; 26(9):1400-10
Rubin L C, “Merchandising Madness: Pills, Promises, and Better Living Through Chemistry,” Journal of Popular Culture, November 2004, 369.
Rules and Regulations, Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products - Part 2 of 3, Federal Register, January 24, 2006.
Schatz M; Leibman C. “Inhaled corticosteroid use and outcomes in pregnancy.” Ann Allergy Asthma Immunol. 2005; 95(3):234-8
Seftel AD, Sun P, Swindle R. “The Prevalence of Hypertension, Hyperlipidemia, Diabetes Mellitus and Depression among Men with Erectile Dysfunction.” Journal of Urology 2004;171:2341-2345.
Stafford R S, “National Trends in Osteoporosis Visits,” Archives of Internal Medicine, July 26, 2004, 1525 – 1530.
Stafford R S, Furberg C D, Finkelstein S N, Cockburn I M, Alehegn T, Ma J, “Impact of Clinical Trail Results on National Trends of Alpha Blockers Prescribing Trends, 1996-2002,” JAMA, January 2004, 54-62.
Stahl S M, “A rash proposal for psychopharmacologists treating bipolar disorder: become an amateur dermatologist,” Clinical Psychiatry News, June 2005, 6.
Statins Don't Increase Breast Carcinoma Risk, Study Says,” NCI Cancer Bulletin, May 11, 2004.
Stempel DA; McLaughlin TP; Stanford RH. ”Treatment patterns for pediatric asthma prior to and after emergency department events.” Pediatr Pulmonol. 2005; 40(4):310-5
“Study Links High Testosterone and Prostate Cancer Link” NCI Cancer Bulletin, May 18, 2004, 1-2.
“Study: Doctors Limited in Rx Training”, CASA Publications, July 7, 2005.
Suissa S; Bernatsky S; Hudson M. “Antirheumatic drug use and the risk of acute myocardial infarction.” Arthritis Rheum. 2006; 55(4):531-6
Suissa S; Hudson M; Ernst P. “Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.” Arthritis Rheum. 2006; 54(5):1435-9
Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. “Economic Impact of Extended-Release Tolterodine Versus Immediate- and Extended-Release Oxybutynin Among Commercially-Insured Persons with Overactive Bladder.” The American Journal of Managed Care 2005;11(6):S140-S149.
Wilensky J, Fiscella RG, Carlson A M, Morris L S, Walt J, “Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data,” Am J Ophthalmo, January 2006, 28-33.
Wingard J R, Wood C A, Sullivan E, Berger M L, Gerth W C, Mansley E C, “Caspofungin versus amphotericin B for candidemia: a pharmacoecomomic analysis,” Clin Ther, June 2005, 960-969.
Xinghua Hu S, Foster T, Kieffaber A, “Pharmacogenomics and personalized medicine: mapping of future value creation,” Biotechniques, September 2005, 1-6
Yazdani C; McLaughlin T; Smeeding JE; Walt J. “Prevalence of treated dry eye disease in a managed care population.” Clin Ther. 2001;23(10):1672-82
